Cellarity Hosts Second Single Cell and AI in Medicine Symposium on May 4, 2023

CAMBRIDGE, Mass., April 13, 2023 – Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today that the second Single Cell and AI in Medicine Symposium (SCAIM23) will take place virtually and in person at Boynton Yards in Somerville on May 4, 2023, from 12:00 pm to 5:30 pm ET.

Cellarity is pleased to announce the distinguished speakers and agenda for SCAIM23 to discuss the state of innovation at the intersection of single-cell analysis, AI, and biology and how this field is impacting drug discovery and the progress of medical science.

A select number of seats are available for the in-person event, register now to reserve your seat, click here. To register for the virtual event, click here.

#SCAIM23 Symposium Agenda

12:00PM – LUNCH & NETWORKING

12:30PM – Welcome and Opening Remarks

Fabrice Chouraqui, Pharm.D., CEO, Cellarity

Laurens Kruidenier, Ph.D., CSO, Cellarity

12:45PM – SESSION 1: Interpretation and Application of Data to Uncover New Biology

Session 1 Moderator: Chad Nusbaum, Ph.D., CTO, Cellarity

Scalable, High-Resolution Single-Nucleus Barcoding for Multi-Modal Spatial Genomics

Fei Chen, Ph.D., Broad Institute of MIT and Harvard

Dissecting Cell Identity Via Network Inference and In Silico Gene Perturbation

Samantha Morris, Ph.D., Washington University in St. Louis

Tracking Cells to Find the Origins of Disease

Sydney Shaffer, M.D., Ph.D., University of Pennsylvania

2:15PM – BREAK

2:30PM – SESSION 2: Applying High Dimensional Data and Machine Learning to the Drug Discovery Process

Session 2 Moderator: Diogo Camacho, Ph.D., VP Computational Biology, Cellarity

Defeating Cancer One Cell at a Time

Andrea Califano, Ph.D., Columbia University

Illuminating the Regulatory Logic of Tissues with Multiplexed Single-Cell Analysis

Zev Gartner, Ph.D., UC San Francisco

Artificial Intelligence Foundation for Therapeutic Science

Marinka Zitnik, Ph.D., Harvard University

4:00PM – Break

4:15PM – SESSION 3: Trends in Industry

Session 3 Moderator: Kat Guillen, Ph.D., Head of Strategy, Cellarity

Tommaso Biancalani, Ph.D., Genentech

Jonah Cool, Ph.D., Chan Zuckerberg Initiative

Enoch Huang, Ph.D., Pfizer

Laurens Kruidenier, Ph.D., Cellarity

5:00PM – KEYNOTE

Competing in the Age of AI: Implications for the Biopharma Industry

Karim Lakhani, Ph.D., Harvard Business School

5:30PM – RECEPTION

For more info, follow Cellarity on Twitter and LinkedIn. Hashtag for the symposium is #SCAIM23.

Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 500 billion genomics data points to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.